Detalhe da pesquisa
1.
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.
Oncology (Williston Park)
; 35(12): 804-811, 2021 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35089000
2.
Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Oncologist
; 24(9): 1209-1218, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796156
3.
Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
Oncologist
; 24(9): 1219-1228, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30808814
4.
Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.
Oncologist
; 22(3): 304-310, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28242792
5.
Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study.
Health Qual Life Outcomes
; 15(1): 160, 2017 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28806963
6.
Clinical outcomes with bevacizumab-containing and non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices.
J Neurooncol
; 122(3): 595-605, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25773061
7.
Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA.
J Comp Eff Res
; 13(2): e230119, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38294335
8.
Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting.
Oncologist
; 18(6): 760-7, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23650020
9.
Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
Leuk Lymphoma
; 64(14): 2316-2323, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37732602
10.
Advance Directives for Patients With Breast Cancer: Applying the Right Info/Right Care/Right Patient/Right Time Oncology Model.
Perm J
; 27(3): 30-36, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37255340
11.
Fostering a High-Functioning Team in Cancer Care Using the 4R Oncology Model: Assessment in a Large Health System and a Blueprint for Other Institutions.
JCO Oncol Pract
; 19(1): e125-e137, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36178937
12.
Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network.
Oncologist
; 16(4): 486-96, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21441299
13.
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
J Manag Care Spec Pharm
; 27(11): 1532-1544, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34714110
14.
Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non-Safety-Net Centers.
JCO Oncol Pract
; 17(8): e1202-e1214, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34375560
15.
Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes.
Qual Life Res
; 19(3): 323-31, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20094804
16.
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States.
Pharmacoeconomics
; 38(9): 941-951, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32383129
17.
Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence.
BMC Urol
; 9: 18, 2009 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-19930578
18.
Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.
Health Sci Rep
; 2(4): e114, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31049419
19.
Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden.
Neurooncol Pract
; 6(2): 103-111, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31386050
20.
Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
J Manag Care Spec Pharm
; 24(6): 565-571, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29451078